Business Context and Reporting Period
DaVita HealthCare Partners Inc. filed this Form 8-K on May 1, 2014, to disclose financial results for the three months ended March 31, 2014. The company operates primarily in Kidney Care and HealthCare Partners (HCP) divisions.
Key Financial Metrics
Consolidated Results (Three Months Ended March 31, 2014):
- Net Income: $183 million
- Net Income Attributable to Noncontrolling Interests: $29 million
- Income Tax Expense: $125 million
- Debt Expense: $106 million
- Consolidated Operating Income: $441 million
Operating Income by Division:
- Kidney Care: $387 million
- HCP: $54 million
HCP Non-GAAP Measures (Adjusted EBITDA):
- Legacy Markets Adjusted EBITDA: $116 million
- New Markets Adjusted EBITDA: $(17) million
- Total HCP Adjusted EBITDA: $99 million
Note: The filing text does not provide specific values for total revenue, cash flow from operations, total debt, or liquidity ratios.
Material Changes
The filing text does not provide comparative data for the prior period (e.g., Q1 2013) or year-over-year percentage changes. Therefore, material changes versus the prior comparable period cannot be determined from this document.
Guidance, Outlook, and Risks
Management Commentary and Non-GAAP Measures: The company utilizes Adjusted EBITDA and adjusted operating income to assess performance for HCP's legacy and new markets. These metrics are defined as net income before income taxes, net debt expense, depreciation, amortization, and unusual charges for loss contingency reserves.
Disclaimers: The company explicitly states that Adjusted EBITDA and adjusted operating income are not GAAP measures, should not be considered in isolation, and may not be indicative of historical results or predictive of future operations or cash flows.
Risks and Contingencies: The reconciliation includes a $3 million loss contingency reserve for Legacy Markets. The filing includes standard legal disclaimers regarding the non-filing status of the information for Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the total revenue figure, as it is not explicitly stated in this 8-K summary.
- Confirm the specific components of the $106 million debt expense to understand interest rate exposure.
- Review the full Q1 2013 results to calculate year-over-year growth rates, which are absent here.
- Investigate the nature of the $3 million loss contingency reserve in Legacy Markets.
- Assess the sustainability of the New Markets segment, which reported a negative Adjusted EBITDA of $17 million.